Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 25Breast Neoplasms 19Multiple Myeloma 17Neoplasm Metastasis 15Lung Neoplasms 15Ovarian Neoplasms 14Lymphoma 14Glioma 14Carcinoma, Renal Cell 14Carcinoma, Non-Small-Cell Lung 12Pancreatic Neoplasms 11Fallopian Tube Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 9Sarcoma 9Medulloblastoma 9Cholangiocarcinoma 9Neuroblastoma 8Glioblastoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Thyroid Neoplasms 7Oropharyngeal Neoplasms 7Uterine Cervical Neoplasms 6Rhabdoid Tumor 6Rectal Neoplasms 6Neuroendocrine Tumors 6Mouth Neoplasms 6Lymphoma, Non-Hodgkin 6

Interventions

Ursodeoxycholic Acid 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Lisinopril 1Exercise 1Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Non-alcoholic Fatty Liver Disease × Magnetic Resonance Spectroscopy × Clear all
NCT04550481 2026-01-21

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Northwestern University

Phase 2 Active not recruiting
45 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡